# Ocythera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ocythera

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.ocythera.com
- Latest round: Seed (Jan 29, 2026)
- Investors on record: 2

## About

Based in Montreal, Canada, Ocythera develops innovative therapies targeting rare bone disorders through unique small molecule inhibitors, aiming to address critical medical needs in this specialized field.Ocythera, founded in 2021 and headquartered in Montreal, Canada, focuses on therapies for rare bone disorders. The company has engaged in 1 deal, with its most recent deal occurring on January 29, 2026. Ocythera was established by individuals with a background in biotechnology, though specific founder details are not provided.Ocythera specializes in developing innovative therapies for rare bone disorders through first-in-class small molecule inhibitors that selectively target enzymes involved in bone disease pathology. The company primarily focuses on Hereditary Multiple Osteochondromas (MO) and Fibrodysplasia Ossificans Progressiva (FOP), which affect bone formation and mobility. Their compounds modulate local retinoic acid signaling pathways, offering a safer therapeutic profile. Ocythera aims to meet the unmet medical needs of patients in North America and Europe who suffer from these genetic disorders.Ocythera's revenue model is structured around strategic partnerships and collaborations with healthcare providers and research institutions, focusing on rare disease therapeutics. The company is expected to generate revenue through licensing agreements and research collaborations. Their products for bone disorders will target healthcare professionals and institutions specializing in genetic diseases, with pricing strategies aligning with industry standards for innovative therapies, linked closely to the advancement of their treatments through clinical phases to regulatory approval and market entry.In January 2026, Ocythera raised an undisclosed amount of Seed funding from new investors adMare Bioinnovations and Investment Quebec. The funding will support research and development of CYP26B1-targeted therapies for rare bone diseases. The company plans to introduce new products focused on these therapies as they advance through clinical trials, while also targeting expansion into new geographic markets in North America and Europe by 2026.

## Funding rounds

- Seed, Jan 29, 2026 — Investment Quebec, adMare Bioinnovations

## Investors

- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Seed
- adMare Bioinnovations (https://capitalatlas.ai/funds/admare-bioinnovations) — Seed